New Eczema Treatment Shows Superior Efficacy
Eczema symptoms cleared faster and in more cases for patients treated with crisaborole topical ointment.
Eczema symptoms cleared faster and in more cases for patients treated with crisaborole topical ointment 2%, a novel non-steroidal phosphodiesterase inhibitor.
The findings were based on data presented at the American Academy of Allergy Asthma & Immunology’s (AAAAI) annual meeting in Los Angeles, CA.
Phase 3 results of the double-blind vehicle-controlled investigation sponsored by manufacturer Anacor Pharmaceuticals appear in the late-breaking abstracts supplement to AAAAI’s Journal of Allergy & Clinical Immunology for February 2016.
Two distinct groups of approximately 750 subjects aged two or older diagnosed with mild to moderate atopic dermatitis were randomized 2:1 to a daily course of topical anti-inflammatory or a control vehicle in a multi-site double blind study.
Severity of symptoms was evaluated at seven-day intervals over 29 days, using the Investigators Static Global Assessment (ISGA) scale.
At Day 29, more crisaborole-treated patients achieved ISGA success than those treated with vehicle (study 1: 32.8% vs 25.4%,P=0.038; study 2: 31.4% vs 18.0%, P<0.001) with a greater percentage of “almost clear/1” or “clear/0” ISGA scores (study 1: 51.7% vs 40.6%, P=0.005; study 2: 48.5% vs 29.7%, P<0.001), the researchers wrote in their study.
“Improvements in pruritus were achieved earlier with crisaborole than with vehicle—and getting relief from itching is so important for our patients — and a greater proportion of crisaborole-treated patients saw improvement for all clinical signs of atopic dermatitis by day 29” said Mark Boguniewicz, MD, of the Division of Pediatric Allergy-Immunology at National Jewish Medical and Research Center in Denver, CO, the lead author.